Antimicrobial Resistance Diagnostics Market, Global, 2024–2030

This Frost & Sullivan report examines the antimicrobial resistance (AMR) diagnostics market in human health. AMR, characterized by bacteria, viruses, and fungi that no longer respond to antimicrobial medications, is one of the top ten global public health threats. When pathogens develop drug resistance, medications become ineffective, leading to infections that may trigger sepsis and significantly increase the risk of severe illness, disability, and death. Covering in vitro diagnostics (IVD) methods, this report includes phenotypic and molecular tests for revenue and forecast estimations. It analyzes the competitive environment, identifying vendors (manufacturers) offering IVD platforms, including instruments, consumables, and informatics. Hospitals, clinics, diagnostic labs, and others encompass key end-user verticals. The analysis offers a region-wise forecast for North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America. The study analyzes the factors driving and restraining the growth of this market and identifies key growth opportunities to help market players and stakeholders build on trends, maximize economic potential, and sustain value. The base year is 2024, and the forecast period is from 2025 to 2030.

Author: Amartya Bose